Table 3.
Comparison of indicators after treatment.
| Index | Author (year) | Experiment | Control | Sample size (EG/CG) | |||||
|---|---|---|---|---|---|---|---|---|---|
| X | S | X | S | Model | I 2 | P | |||
| E2 (pmol/L) | WQF (2021) | 103.41 | 11.22 | 125.46 | 14.24 | 30/30 | Random | 77% | <0.0001 |
| DLL (2021) | 103.23 | 11.04 | 125.52 | 14.33 | 47/47 | ||||
| TYY (2021) | 102.12 | 10.12 | 128.12 | 14.21 | 50/50 | ||||
| LN (2020) | 103.54 | 10.98 | 125.48 | 14.27 | 88/87 | ||||
| ZYY (2021) | 103.52 | 10.94 | 125.46 | 14.25 | 30/30 | ||||
| LDP (2022) | 125.44 | 30.42 | 172.44 | 30.83 | 65/65 | ||||
| P (nmol/L) | WQF (2021) | 0.41 | 0.16 | 0.61 | 0.18 | 30/30 | Fixed | 0.0% | <0.0001 |
| DLL (2021) | 0.39 | 0.15 | 0.6 | 0.21 | 47/47 | ||||
| TYY (2021) | 0.39 | 0.11 | 0.64 | 0.18 | 50/50 | ||||
| LN (2020) | 0.41 | 0.16 | 0.61 | 0.19 | 88/87 | ||||
| ZYY (2021) | 0.38 | 0.14 | 0.59 | 0.17 | 30/30 | ||||
| LH (IU/L) | WQF (2021) | 5.76 | 1.71 | 5.42 | 1.63 | 30/30 | Random | 95% | 0.2740 |
| DLL (2021) | 5.75 | 1.68 | 5.37 | 1.57 | 47/47 | ||||
| TYY (2021) | 4.57 | 1.01 | 5.53 | 1.35 | 50/50 | ||||
| LN (2020) | 5.76 | 1.64 | 5.82 | 1.71 | 88/87 | ||||
| ZYY (2021) | 5.74 | 1.62 | 5.81 | 1.69 | 30/30 | ||||
| LDP (2022) | 3.25 | 1.21 | 6.15 | 1.44 | 65/65 | ||||
| FSH (IU/L) | WQF (2021) | 5.52 | 1.73 | 5.69 | 1.62 | 30/30 | Random | 90% | 0.0778 |
| DLL (2021) | 5.51 | 1.68 | 5.72 | 1.59 | 47/47 | ||||
| TYY (2021) | 4.45 | 1.02 | 5.55 | 1.13 | 50/50 | ||||
| LN (2020) | 5.52 | 1.75 | 5.56 | 1.85 | 88/87 | ||||
| ZYY (2021) | 5.51 | 1.73 | 5.54 | 1.83 | 30/30 | ||||
| LDP (2022) | 5.11 | 1.25 | 7.44 | 1.83 | 65/65 | ||||
| CA125 (IU/ml) | WQF (2021) | 42.22 | 11.43 | 62.43 | 11.69 | 30/30 | Random | 91% | <0.0001 |
| DLL (2021) | 42.16 | 11.58 | 62.56 | 11.78 | 47/47 | ||||
| MD (2017) | 51.31 | 23.46 | 62.23 | 19.58 | 40/40 | ||||
| WM (2019) | 42.02 | 11.65 | 63.25 | 12.08 | 85/85 | ||||
| BXH (2020) | 42.01 | 9.32 | 63.36 | 11.43 | 53/53 | ||||
| LN (2020) | 25.42 | 3.98 | 35.67 | 5.22 | 88/87 | ||||
| ZWX (2021) | 41.06 | 10.32 | 53.97 | 11.08 | 38/37 | ||||
| LDP (2022) | 18.33 | 10.62 | 25.74 | 10.36 | 65/65 | ||||
| CA199 (IU/ml) | WQF (2021) | 26.22 | 4.63 | 35.54 | 5.67 | 30/30 | Fixed | 31% | <0.0001 |
| LN (2020) | 26.13 | 4.62 | 35.83 | 5.69 | 88/87 | ||||
| ZWX (2021) | 40.36 | 9.88 | 54.13 | 10.75 | 38/37 | ||||
| MPP2 (µg/L) | WQF (2021) | 129.65 | 12.76 | 171.58 | 19.87 | 30/30 | Fixed | 0.0% | <0.0001 |
| DLL (2021) | 129.81 | 13.05 | 171.69 | 20.06 | 47/47 | ||||
| TYY (2021) | 128.44 | 13.02 | 171.12 | 18.99 | 50/50 | ||||
| LN (2020) | 129.98 | 12.97 | 172.24 | 19.74 | 88/87 | ||||
| Gal-3 (ng/L) | WQF (2021) | 5.68 | 2.31 | 6.89 | 2.24 | 30/30 | Fixed | 0.0% | <0.0001 |
| DLL (2021) | 5.7 | 2.25 | 6.94 | 2.16 | 47/47 | ||||
| TYY (2021) | 5.32 | 2.02 | 6.86 | 2.04 | 50/50 | ||||
| LN (2020) | 5.69 | 2.31 | 6.93 | 3.14 | 88/87 | ||||
| VEGF (pg/ml) | WQF (2021) | 85.65 | 50.67 | 121.58 | 82.84 | 30/30 | Fixed | 0.0% | <0.0001 |
| DLL (2021) | 85.77 | 50.73 | 122.36 | 83.42 | 47/47 | ||||
| LN (2020) | 85.78 | 53.46 | 121.85 | 89.37 | 88/87 | ||||
| MPP9 (ng/L) | DLL (2021) | 565.47 | 220.75 | 690.26 | 293.42 | 47/47 | Fixed | 0.0% | <0.0001 |
| TYY (2021) | 566.54 | 236.23 | 680.12 | 282.12 | 50/50 | ||||
| LN (2020) | 568.38 | 237.53 | 687.34 | 298.47 | 88/87 | ||||
| Diameter (cm) | MD (2017) | 2.46 | 1.04 | 2.97 | 1.22 | 40/40 | Random | 98% | 0.0003 |
| WM (2019) | 1.02 | 0.56 | 2.87 | 0.61 | 85/85 | ||||
| BXH (2020) | 1.01 | 0.47 | 2.73 | 0.62 | 53/53 | ||||
| LN (2020) | 0.69 | 0.25 | 1.25 | 0.31 | 88/87 | ||||
| ZWX (2021) | 0.72 | 0.19 | 1.24 | 0.28 | 38/37 | ||||
| ZYY (2021) | 0.67 | 0.23 | 1.23 | 0.29 | 30/30 | ||||
| VAS | ZJ (2021) | 2.03 | 0.2 | 2.79 | 0.26 | 43/43 | Random | 98% | <0.0005 |
| WM (2019) | 2.94 | 0.87 | 5.63 | 0.89 | 85/85 | ||||
| BXH (2020) | 2.92 | 0.69 | 5.64 | 0.98 | 53/53 | ||||
| LN (2020) | 1.58 | 0.42 | 2.18 | 0.81 | 88/87 | ||||
| ZWX (2021) | 1.17 | 0.26 | 2.39 | 0.47 | 38/37 | ||||
| ZYY (2021) | 1.56 | 0.41 | 2.16 | 0.79 | 30/30 | ||||
| ORT (days) | ZYH (2015) | 13.27 | 2.49 | 18.58 | 2.91 | 63/63 | Random | 97% | 0.0976 |
| JX (2021) | 13.38 | 3.60 | 14.69 | 3.15 | 88/89 | ||||
| MRT (days) | ZYH (2015) | 26.37 | 4.12 | 33.61 | 3.29 | 63/63 | Random | 97% | 0.0585 |
| JX (2021) | 26.48 | 4.23 | 28.72 | 3.40 | 88/89 | ||||
| ADR (%) | DLL (2021) | 3 | 5 | 47/47 | Fixed | 13% | 0.0097 | ||
| ZYH (2015) | 6 | 17 | 63/63 | ||||||
| WM (2019) | 19 | 23 | 85/85 | ||||||
| LN (2020) | 6 | 14 | 88/87 | ||||||
| LDP (2022) | 5 | 4 | 65/65 | ||||||
VAS, visual analogue scale; ORT, oviating recovery time; MRT, menses recovery time; ADR, adverse reaction.